Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers

Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

What is claimed is: 
     
         1 . A method of treating a patient who has cancer, comprising administering to said patient a composition comprising activated T cells that kill cancer cells that present on the surface a peptide consisting of the amino acid sequence of RLLEGDFSL (SEQ ID NO: 2) in a complex with an MHC class I molecule, wherein the cancer is uterine endometrial cancer (UEC), esophageal cancer (OSCAR), ovarian cancer (OC), squamous cell non-small cell lung cancer (NSCLCsquam), NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam (NSCLCother), head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), gallbladder cancer (GBC), colorectal cancer (CRC), non-small cell lung cancer adenocarcinoma (NSCLCadeno), or breast cancer (BRCA). 
     
     
         2 . The method of  claim 1 , wherein the cancer is UEC. 
     
     
         3 . The method of  claim 1 , wherein the cancer is OSCAR. 
     
     
         4 . The method of  claim 1 , wherein the cancer is OC. 
     
     
         5 . The method of  claim 1 , wherein the cancer NSCLCsquam. 
     
     
         6 . The method of  claim 1 , wherein the cancer is NSCLCother. 
     
     
         7 . The method of  claim 1 , wherein the cancer is HNSCC. 
     
     
         8 . The method of  claim 1 , wherein the cancer is HCC. 
     
     
         9 . The method of  claim 1 , wherein the cancer is GBC. 
     
     
         10 . The method of  claim 1 , wherein the cancer is CRC. 
     
     
         11 . The method of  claim 1 , wherein the cancer is NSCLCadeno. 
     
     
         12 . The method of  claim 1 , wherein the cancer is BRCA. 
     
     
         13 . The method of  claim 1 , wherein the composition further comprises at least one immune stimulating cytokine selected from the group consisting of EOTAXIN, G-CSF, GM-CSF, INF-γ, interleukin (IL)-1α, M-CSF, IL-10, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12 (p40), IL-13, IL-18, IL-15, IL-17, IP-10, MIP-2, KC, LIF, LIX, MCP-1, MIP-1α, MIP-1β, MIG, RANTES, TNFα, IL-12 (p70), VEGF, IL-9, and IL-21. 
     
     
         14 . The method of  claim 1 , further comprising administering at least one immune stimulating cytokine selected from the group consisting of EOTAXIN, G-CSF, GM-CSF, INF-γ, interleukin (IL)-1α, M-CSF, IL-10, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12 (p40), IL-13, IL-18, IL-15, IL-17, IP-10, MIP-2, KC, LIF, LIX, MCP-1, MIP-1α, MIP-1β, MIG, RANTES, TNFα, IL-12 (p70), VEGF, IL-9, and IL-21. 
     
     
         15 . The method of  claim 13 , wherein the at least one immune stimulating cytokine is IL-2. 
     
     
         16 . The method of  claim 13 , wherein the at least one immune stimulating cytokine is IL-15. 
     
     
         17 . The method of  claim 13 , wherein the at least one immune stimulating cytokine is IL-21. 
     
     
         18 . The method of  claim 14 , wherein the at least one immune stimulating cytokine is IL-2. 
     
     
         19 . The method of  claim 14 , wherein the at least one immune stimulating cytokine is IL-15. 
     
     
         20 . The method of  claim 14 , wherein the at least one immune stimulating cytokine is IL-21.